Literature DB >> 21889254

Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey.

S Bavbek1, I Yilmaz, G Celik, O Aydin, F Ö Erkekol, A Orman, E Kurt, D Ediger, B Dursun, O Abadoğlu, F Ozşeker, E Akkaya, G P Karakiş, S Canbakan, S Yüksel, Z Misirligil.   

Abstract

BACKGROUND: There are no country-based data focused on aspirin (ASA)-exacerbated respiratory disease (AERD) in Turkey.
OBJECTIVE: To assess the prevalence of AERD in adult patients with asthma.
METHODS: A structured questionnaire was administered via face-to-face interview by a specialist in pulmonology/allergy at seven centres across Turkey.
RESULTS: A total of 1344 asthma patients (F/M: 1081/263: 80.5%/19.5%, mean age: 45.7 ± 14.2 years) were enrolled. Atopy rate was 47%. Prevalence of allergic rhinitis, chronic rhinosinusitis/rhinitis, and nasal polyposis (NP) were 49%, 69% and 20%, respectively. Of 270 patients with NP, 171 (63.3%) reported previous nasal polypectomy and 40 (25%) had a history of more than three nasal polypectomies. Aspirin hypersensitivity was diagnosed in 180 (13.6%) asthmatic patients, with a reliable history in 145 (80.5%), and oral ASA provocation test in 35 (19.5%) patients. Clinical presentations of ASA hypersensitivity were respiratory in 76% (n=137), respiratory/cutaneous in 15% (n=27), and systemic in 9% (n=16) of the patients. Multivariate analysis indicated that a family history of ASA hypersensitivity (p: 0.001, OR: 3.746, 95% CI: 1.769-7.929), history of chronic rhinosinusitis/rhinitis (p: 0.025, OR: 1.713, 95% CI: 1.069-2.746) and presence of NP (p<0.001, OR: 7.036, 95% CI: 4.831-10.247) were independent predictors for AERD.
CONCLUSION: This cross-sectional survey showed that AERD is highly prevalent among adult asthmatics and its prevalence seems to be affected by family history of ASA hypersensitivity, history of rhinosinusitis and presence of NP.
Copyright © 2011 SEICAP. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889254     DOI: 10.1016/j.aller.2011.05.015

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  6 in total

Review 1.  Complementary Participation of Genetics and Epigenetics in Development of NSAID-exacerbated Respiratory Disease.

Authors:  Jong Uk Lee; Jong Sook Park; Hun Soo Chang; Choon Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2019-11       Impact factor: 5.764

2.  NSAID-exacerbated respiratory disease: a population study.

Authors:  Heidi Andersén; Pinja Ilmarinen; Jasmin Honkamäki; Leena E Tuomisto; Hanna Hisinger-Mölkänen; Helena Backman; Bo Lundbäck; Eva Rönmark; Tari Haahtela; Anssi Sovijärvi; Lauri Lehtimäki; Päivi Piirilä; Hannu Kankaanranta
Journal:  ERJ Open Res       Date:  2022-01-24

3.  Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010.

Authors:  Henriette Steppuhn; Ute Langen; Christa Scheidt-Nave; Thomas Keil
Journal:  BMC Pulm Med       Date:  2013-07-12       Impact factor: 3.317

Review 4.  Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden.

Authors:  Achim Beule
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

5.  MS4A2-rs573790 Is Associated With Aspirin-Exacerbated Respiratory Disease: Replicative Study Using a Candidate Gene Strategy.

Authors:  Gandhi F Pavón-Romero; Gloria Pérez-Rubio; Fernando Ramírez-Jiménez; Enrique Ambrocio-Ortiz; Elisé Bañuelos-Ortiz; Norma Alvarado-Franco; Karen E Xochipa-Ruiz; Elizabeth Hernández-Juárez; Beatriz A Flores-García; Ángel E Camarena; Luis M Terán; Ramcés Falfán-Valencia
Journal:  Front Genet       Date:  2018-09-11       Impact factor: 4.599

Review 6.  NSAID-induced reactions: classification, prevalence, impact, and management strategies.

Authors:  Natalia Blanca-Lopez; Victor Soriano; Elena Garcia-Martin; Gabriela Canto; Miguel Blanca
Journal:  J Asthma Allergy       Date:  2019-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.